



Case 1614

#3
mu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Carillo et al.

Title: Method of Cancer Treatment By P53 Protein Control
Serial No. 09/405,920
Filing Date: September 24, 1999
Group Art Unit: 1614

RECEIVED

JAN 21 2000

To: Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING (37 CFR § 1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: 1-14-2000

Paula L. Dickey
(Type or print name of person mailing paper)

Paula L. Dickey
(Signature of person mailing paper)

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR §§ 1.97 AND 1.98

Dear Sir:

Applicants submit herewith a list of patents and publications, and copies thereof as required by 37 CFR § 1.98, which Applicants believe the Examiner may consider to be material to the patentability of claims of this application and for which there may be a duty to disclose in accordance with 37 CFR § 1.56.

While the patents and publications disclosed herein may be "material" within the meaning of 37 CFR § 1.56, Applicants' inclusion thereof in this Statement is not intended to constitute an admission that any such patent or publication is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that the information cited is material to patentability as defined in 37 CFR § 1.56(b).


Applicants believe that the claims in the present application are patently distinguishable over the patents and publications listed on the attached Information Disclosure Citation Form.

This Information Disclosure Statement is being filed before the first Office Action on the merits of this application and accordingly, pursuant to 37 CFR § 1.97 (b)(3), this statement requires neither a fee nor a certification.

Dated

1/13/2000

Respectfully submitted,



Rachel H. Rondinelli, Ph.D.
Agent for Applicants
Registration No.: 45,052

Aventis Pharmaceutical Products Inc.
P.O. Box 5093, Mail Stop 3C43
500 Arcola Road
Collegeville, PA 19426-0997
Telephone: (610) 454-3178
Facsimile: (610) 454-3808